Within the two phase 3 studies, PX-171-0009 (ASPIRE) and 2011-003 (ENDEAVOR), the eligibility criteria allowed for the enrollment of multiple myeloma patients with baseline mild hepatic impairment (alanine aminotransferase [ALT]/aspartate aminotransferase (AST) >upper limit of normal (ULN) or total bilirubin >ULN) without a starting dose adjustment [4, 5]. This evidence concerns the gene GPT and AL amyloidosis.